China has given the go-ahead for researchers to begin human safety tests of an experimental coronavirus vaccine in the race to develop a shot against the COVID-19 epidemic that has killed more than 7,000 people worldwide.
Researchers at China's Academy of Military Medical Sciences, - affiliated to the Chinese People's Liberation Army (PLA) - received approval to launch early-stage clinical trials of the potential vaccine starting this week, the ruling Communist Party's People's Daily reported on Tuesday.
Scientists in the United States said on Monday that clinical trials had begun for a vaccine developed by its National Institute of Allergy and Infectious Diseases and the US biotech firm Moderna.
Details in the Chinese clinical trial registration database show that a "Phase 1" test that will examine whether experimental shot is safe in humans aims to recruit 108 healthy people to take part between March 16 and December 31.
The trial will be conducted by China's Academy of Military Medical Sciences and the Hong Kong-listed biotech firm CanSino Biologics, the database showed.
Experts at the World Health Organization say they do not expect any fully tested and approved vaccine to reach the market until the middle of next year.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
5 Shocking Revelations From Hinduja Family's Trial In Swiss Court Universal Coronavirus Vaccine? New Jab Targets Even Unknown Threats A New All-In-One Vaccine May Prove Effective Against All Coronaviruses Bangladesh Imposes Curfew, Deploys Military As 105 Die In Protests "Jindal Group Executive Showed Porn, Groped Me On Flight": Woman To NDTV Over 300 Indian Students Return Home As 105 Bangladeshis Killed In Protests Trump Says Spoke With Zelensky, Pledges To "End The War" Joe Biden Is The Best Person To Take On Trump, Says His Campaign Wife Among Two Jailed For Life For Man's Murder In Gurugram: Cops Track Latest News Live on NDTV.com and get news updates from India and around the world.